All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Immune checkpoint molecules, like CTLA-4 and PD-1/PD-L1, act at different stages of T-cell activation and lead to a dampened T-cell response. In response to a normal immune challenge, this pathway prevents hyperstimulation, while in malignancy this can halt immune responses, enabling unimpeded tumor progression. Checkpoint inhibitors target these molecules to reinstate the immune response.